Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Triple Negative Breast Neoplasms 1Skin Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Carcinoma 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × MAPRE1 protein, human × Clear all
NCT04349436 2026-04-22

ARTACUS

Replimune, Inc.

Phase 1/2 Active not recruiting
69 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell

NCT06216938 2026-04-13

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

University of Pittsburgh

Phase EARLY_PHASE1 Recruiting
25 enrolled
Dermatologic

Melanoma

NCT06067061 2025-06-11

neoBREASTIM

Institut Curie

Phase 1/2 Terminated
2 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡